<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
<url>
<loc>https://de.prisysbiotech.com/</loc>
<image:image>
<image:title>Nicht  -  Mensch  Primas  Forschung  Plattform  &amp;  CRO | PRISYS  Biotechnologie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/logo.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/</loc>
<image:image>
<image:title>NHP-Pharmakologie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/list/n20240227154733ebf63.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/pk-pd-adme/</loc>
<image:image>
<image:title>PK PDADME</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/p202303211449418813566.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/safety-evaluation/</loc>
<image:image>
<image:title>Sicherheitsbewertung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/p202303211451568197109.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/translation-research/</loc>
<image:image>
<image:title>Translation Research</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/p202303211454114300368.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/biosafety-research/</loc>
<image:image>
<image:title>Biosicherheitsforschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/p202303211456214933321.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/pk-pd-adme/toxicokinetics.html</loc>
<image:image>
<image:title>Toxicokinetics</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/toxicokinetics70843.jpg</image:loc>
</image:image>
<image:image>
<image:title>Toxicokinetics</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/toxicokinetics70843.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/the-nhp-pharmacology-of-prisys.html</loc>
<image:image>
<image:title>The NHP Pharmacology Of Prisys</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/the-nhp-pharmacology-of-prisysb465a.jpg</image:loc>
</image:image>
<image:image>
<image:title>The NHP Pharmacology Of Prisys</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/the-nhp-pharmacology-of-prisysb465a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/safety-evaluation/dose-range-finding-test.html</loc>
<image:image>
<image:title>Dose Range Finding Test</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/dose-range-finding-teste7c22.jpg</image:loc>
</image:image>
<image:image>
<image:title>Dose Range Finding Test</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/dose-range-finding-teste7c22.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/safety-evaluation/single-dose-repeated-dose-toxicity-testing.html</loc>
<image:image>
<image:title>Single-dose &amp; Repeated Dose Toxicity Testing</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/single-dose-repeated-dose-toxicity-testinga0b95.jpg</image:loc>
</image:image>
<image:image>
<image:title>Single-dose &amp; Repeated Dose Toxicity Testing</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/single-dose-repeated-dose-toxicity-testinga0b95.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/what-is-a-nhp-study.html</loc>
<image:image>
<image:title>What Is A NHP Study</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/what-is-a-nhp-study0fe0f.jpg</image:loc>
</image:image>
<image:image>
<image:title>What Is A NHP Study</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/what-is-a-nhp-study0fe0f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/pk-pd-adme/pharmacokinetics.html</loc>
<image:image>
<image:title>Pharmacokinetics</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/pharmacokineticsa44cd.jpg</image:loc>
</image:image>
<image:image>
<image:title>Pharmacokinetics</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/pharmacokineticsa44cd.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/coagulation-hemostasis-nonhuman-primates.html</loc>
<image:image>
<image:title>Coagulation/Hemostasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/coagulation-hemostasis-nonhuman-primates63c5ab02-c0b4-4eb9-b521-9658b5017498.jpg</image:loc>
</image:image>
<image:image>
<image:title>Coagulation/Hemostasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/coagulation-hemostasis-nonhuman-primates63c5ab02-c0b4-4eb9-b521-9658b5017498.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/pk-pd-adme/adme.html</loc>
<image:image>
<image:title>ADME</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/adme55f5d.jpg</image:loc>
</image:image>
<image:image>
<image:title>ADME</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/adme55f5d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/non-human-primate-model-renal-ischemia.html</loc>
<image:image>
<image:title>Non-Human Primate Model Renal Ischemia Reperfusion Injury (AKI To CKD Transition)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/non-human-primate-model-renal-ischemia7ddb4a21-f360-4251-a51c-3cdb367eb3ad.jpg</image:loc>
</image:image>
<image:image>
<image:title>Non-Human Primate Model Renal Ischemia Reperfusion Injury (AKI To CKD Transition)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/non-human-primate-model-renal-ischemia7ddb4a21-f360-4251-a51c-3cdb367eb3ad.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/biosafety-research/biosafetyresearch.html</loc>
<image:image>
<image:title>Biosafety Research</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/biosafetyresearchcd745.jpg</image:loc>
</image:image>
<image:image>
<image:title>Biosafety Research</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/biosafetyresearchcd745.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/mcao-nhp-model.html</loc>
<image:image>
<image:title>Middle Cerebral Artery Occlusion (MCAO) NHP Model Of Stoke &amp; Brain Ischemia</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/mcao-nhp-model0cf8cbb0-48b5-473b-b725-fd749c9c69ca.jpg</image:loc>
</image:image>
<image:image>
<image:title>Middle Cerebral Artery Occlusion (MCAO) NHP Model Of Stoke &amp; Brain Ischemia</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/mcao-nhp-model0cf8cbb0-48b5-473b-b725-fd749c9c69ca.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/nhp-asthma-atopic-dermatitis-model.html</loc>
<image:image>
<image:title>NHP Asthma/atopic Dermatitis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/nhp-asthma-atopic-dermatitis-model6bc15051-9b18-470b-a3ed-3a035fb26acc.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Asthma/atopic Dermatitis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/nhp-asthma-atopic-dermatitis-model6bc15051-9b18-470b-a3ed-3a035fb26acc.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/hemophilia-a-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Hemophilia A Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/hemophilia-a-nonhuman-primates-disease-model4c747716-98c5-4ef0-a508-55e7790a46ff.jpg</image:loc>
</image:image>
<image:image>
<image:title>Hemophilia A Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/hemophilia-a-nonhuman-primates-disease-model4c747716-98c5-4ef0-a508-55e7790a46ff.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/safety-evaluation/new-and-modified-applications.html</loc>
<image:image>
<image:title>New And Modified Applications</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/new-and-modified-applicationsab01b425-decb-46a1-90d1-e5fee60f1327.jpg</image:loc>
</image:image>
<image:image>
<image:title>New And Modified Applications</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/new-and-modified-applicationsab01b425-decb-46a1-90d1-e5fee60f1327.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/tdar-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>T Cell Dependent Antibody Response(TDAR) Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/tdar-nonhuman-primates-disease-modelae31c.jpg</image:loc>
</image:image>
<image:image>
<image:title>T Cell Dependent Antibody Response(TDAR) Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/tdar-nonhuman-primates-disease-modelae31c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/rheumatoid-arthritis-nhp-model.html</loc>
<image:image>
<image:title>Rheumatoid Arthritis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/rheumatoid-arthritis-nhp-model438fa.jpg</image:loc>
</image:image>
<image:image>
<image:title>Rheumatoid Arthritis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/rheumatoid-arthritis-nhp-model438fa.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/psoriasis-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Psoriasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/psoriasis-nonhuman-primates-disease-model6e94c.jpg</image:loc>
</image:image>
<image:image>
<image:title>Psoriasis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/psoriasis-nonhuman-primates-disease-model6e94c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/translation-research/nhpresources.html</loc>
<image:image>
<image:title>NHP Resources</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/nhpresources90325.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Resources</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/nhpresources90325.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/heart-failure-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Acute Myocardial Infarction/Heart Failure Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/acute-myocardial-infarction-heart-failure3d3bf8b7-5a0c-4f9d-8841-7f98a51cf834.jpg</image:loc>
</image:image>
<image:image>
<image:title>Acute Myocardial Infarction/Heart Failure Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/acute-myocardial-infarction-heart-failure3d3bf8b7-5a0c-4f9d-8841-7f98a51cf834.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/embolism-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/pulmonary-artery-hypertension-embolism9d266a3e-e0d5-46d2-85d6-aad09f286515.jpg</image:loc>
</image:image>
<image:image>
<image:title>Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/pulmonary-artery-hypertension-embolism9d266a3e-e0d5-46d2-85d6-aad09f286515.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/myopia-hyperopia-nhp-model.html</loc>
<image:image>
<image:title>Myopia Hyperopia Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/myopia-hyperopia-nhp-modela0553861-d7d5-4d4f-af65-68d25533d6ef.jpg</image:loc>
</image:image>
<image:image>
<image:title>Myopia Hyperopia Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/myopia-hyperopia-nhp-modela0553861-d7d5-4d4f-af65-68d25533d6ef.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/nhp-lung-fibrosis-model.html</loc>
<image:image>
<image:title>NHP Lung Fibrosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nhp-lung-fibrosis-model25cd4.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Lung Fibrosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nhp-lung-fibrosis-model25cd4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/amd-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>AMD Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/amd-nonhuman-primates-disease-modelf663a012-d546-4fbb-8d78-834cea736255.jpg</image:loc>
</image:image>
<image:image>
<image:title>AMD Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/amd-nonhuman-primates-disease-modelf663a012-d546-4fbb-8d78-834cea736255.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/pk-pd-adme/pharmacodynamics.html</loc>
<image:image>
<image:title>Pharmacodynamics</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/pharmacodynamics620d3.jpg</image:loc>
</image:image>
<image:image>
<image:title>Pharmacodynamics</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/pharmacodynamics620d3.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/inflammatory-bowel-nhp-disease-model.html</loc>
<image:image>
<image:title>Inflammatory Bowel Disease Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/inflammatory-bowel-nhp-disease-modelf4c414ff-a224-4634-a994-b8ba7a18a488.jpg</image:loc>
</image:image>
<image:image>
<image:title>Inflammatory Bowel Disease Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/inflammatory-bowel-nhp-disease-modelf4c414ff-a224-4634-a994-b8ba7a18a488.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/translation-research/translational-studies.html</loc>
<image:image>
<image:title>Translational Studies</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/translational-studiesd565144e-fcec-4437-afeb-42982ae7bab9.jpg</image:loc>
</image:image>
<image:image>
<image:title>Translational Studies</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/translational-studiesd565144e-fcec-4437-afeb-42982ae7bab9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/glaucoma-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Glaucoma Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/glaucoma-nonhuman-primates-disease-model092df254-f018-4636-a429-8344948a9978.jpg</image:loc>
</image:image>
<image:image>
<image:title>Glaucoma Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/glaucoma-nonhuman-primates-disease-model092df254-f018-4636-a429-8344948a9978.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/epilepsy-nhp-model.html</loc>
<image:image>
<image:title>Epilepsy Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/epilepsy-nhp-model4f142.jpg</image:loc>
</image:image>
<image:image>
<image:title>Epilepsy Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/epilepsy-nhp-model4f142.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/nhp-monkey-disease-models.html</loc>
<image:image>
<image:title>NHP(monkey) Disease Models</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nhp-monkey-disease-models0f6a0.png</image:loc>
</image:image>
<image:image>
<image:title>NHP(monkey) Disease Models</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nhp-monkey-disease-models0f6a0.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/delayed-type-hypersensitivity-dth-nonhuman.html</loc>
<image:image>
<image:title>Delayed-type Hypersensitivity (DTH) Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/delayed-type-hypersensitivity-dth-nonhuman90003.jpg</image:loc>
</image:image>
<image:image>
<image:title>Delayed-type Hypersensitivity (DTH) Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/delayed-type-hypersensitivity-dth-nonhuman90003.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/uveitis-nonhuman-primates-disease-model.html</loc>
<image:image>
<image:title>Uveitis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/uveitis-nonhuman-primates-disease-model0ba7fdbf-75a4-42f7-8990-e9daa0c176b0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Uveitis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/uveitis-nonhuman-primates-disease-model0ba7fdbf-75a4-42f7-8990-e9daa0c176b0.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/safety-evaluation/immunotoxicity.html</loc>
<image:image>
<image:title>Immunotoxicity</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/immunotoxicitya758bdcf-a01c-4970-a80d-758e345ae77f.jpg</image:loc>
</image:image>
<image:image>
<image:title>Immunotoxicity</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/immunotoxicitya758bdcf-a01c-4970-a80d-758e345ae77f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/safety-evaluation/toxicology.html</loc>
<image:image>
<image:title>Toxicology</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/toxicologycdb96.jpg</image:loc>
</image:image>
<image:image>
<image:title>Toxicology</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/toxicologycdb96.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/neuropathic-pain-nhp-model.html</loc>
<image:image>
<image:title>Neuropathic Pain Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/neuropathic-pain-nhp-modela385dae9-a466-42bb-9982-13db42e0581b.jpg</image:loc>
</image:image>
<image:image>
<image:title>Neuropathic Pain Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/neuropathic-pain-nhp-modela385dae9-a466-42bb-9982-13db42e0581b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/nhp-chronic-obstructive-pulmonary-disease.html</loc>
<image:image>
<image:title>NHP Chronic Obstructive Pulmonary Disease (COPD) Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/nhp-chronic-obstructive-pulmonary-disease08000f1b-42f7-4c7d-9ba5-6f15c54993c9.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Chronic Obstructive Pulmonary Disease (COPD) Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/nhp-chronic-obstructive-pulmonary-disease08000f1b-42f7-4c7d-9ba5-6f15c54993c9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/non-human-primate.html</loc>
<image:image>
<image:title>Non-Human Primate (NHP)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
<image:image>
<image:title>Non-Human Primate (NHP)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/nhp-non-alcoholic-steatohepatitis-nash-model.html</loc>
<image:image>
<image:title>NHP Non-Alcoholic Steatohepatitis (NASH) Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/small/nhp-non-alcoholic-steatohepatitis-nash-model7332a6f4-bc77-45be-bf2b-07178c46a62a.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Non-Alcoholic Steatohepatitis (NASH) Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/nhp-non-alcoholic-steatohepatitis-nash-model7332a6f4-bc77-45be-bf2b-07178c46a62a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/multiple-sclerosis-nhp-model.html</loc>
<image:image>
<image:title>Multiple Sclerosis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/multiple-sclerosis-nhp-modelac9f75fb-b6ef-46d4-867c-1ad7b769490b.jpg</image:loc>
</image:image>
<image:image>
<image:title>Multiple Sclerosis Nonhuman Primates Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/multiple-sclerosis-nhp-modelac9f75fb-b6ef-46d4-867c-1ad7b769490b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/clearpoint/clearpoint-navigation-for-cns-research.html</loc>
<image:image>
<image:title>ClearPoint Navigation For CNS Research</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/clearpoint-navigation-for-cns-researchf4cb9.jpg</image:loc>
</image:image>
<image:image>
<image:title>ClearPoint Navigation For CNS Research</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/clearpoint-navigation-for-cns-researchf4cb9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/translation-research/ai-based-nhp-behavior-analysis-system.html</loc>
<image:image>
<image:title>AI-based NHP Behavior Analysis System</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/ai-based-nhp-behavior-analysis-systema5d80.png</image:loc>
</image:image>
<image:image>
<image:title>AI-based NHP Behavior Analysis System</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/ai-based-nhp-behavior-analysis-systema5d80.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/parkinson-s-disease-model.html</loc>
<image:image>
<image:title>Parkinson&#39;s Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/parkinson-s-disease-model9ce85.jpg</image:loc>
</image:image>
<image:image>
<image:title>Parkinson&#39;s Disease Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/parkinson-s-disease-model9ce85.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/translation-research/clinical-imaging.html</loc>
<image:image>
<image:title>Klinische Bildgebung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/clinical-imaging585d0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Klinische Bildgebung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/clinical-imaging585d0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/small/clinical-imagingb514bd15-133f-4e9b-a75a-0e1cbbc1f4f0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/clinical-imagingb514bd15-133f-4e9b-a75a-0e1cbbc1f4f0.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/small/clinical-imagingb9ae57aa-6754-41ce-822c-46e3f1c3d84a.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/clinical-imagingb9ae57aa-6754-41ce-822c-46e3f1c3d84a.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/small/clinical-imaginga1e6f856-06fb-4365-aa1c-53949acb37af.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/clinical-imaginga1e6f856-06fb-4365-aa1c-53949acb37af.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/small/clinical-imagingb127b97f-7b00-4335-b905-64e36f57247d.jpg</image:loc>
</image:image>
<image:image>
<image:title>Clinical Imaging</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202439406/clinical-imagingb127b97f-7b00-4335-b905-64e36f57247d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/hyperlipoidemia-model.html</loc>
<image:image>
<image:title>Hyperlipoidemia Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/hyperlipoidemia-modeldc1b0.png</image:loc>
</image:image>
<image:image>
<image:title>Hyperlipoidemia Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/hyperlipoidemia-modeldc1b0.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/a-v-shunt-model.html</loc>
<image:image>
<image:title>A-V Shunt Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/a-v-shunt-modelef93d.jpg</image:loc>
</image:image>
<image:image>
<image:title>A-V Shunt Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/a-v-shunt-modelef93d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/endometriosis-model.html</loc>
<image:image>
<image:title>Endometriosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/endometriosis-modeldd994.png</image:loc>
</image:image>
<image:image>
<image:title>Endometriosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/endometriosis-modeldd994.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/type-1-diabetes-mellitus-model.html</loc>
<image:image>
<image:title>Type 1 Diabetes Mellitus Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/type-1-diabetes-mellitus-modelbc16f.png</image:loc>
</image:image>
<image:image>
<image:title>Type 1 Diabetes Mellitus Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/type-1-diabetes-mellitus-modelbc16f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/type-2-diabetes-mellitus-model.html</loc>
<image:image>
<image:title>Modell f&#252;r Typ-2-Diabetes mellitus</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/type-2-diabetes-mellitus-model5981d.png</image:loc>
</image:image>
<image:image>
<image:title>Modell f&#252;r Typ-2-Diabetes mellitus</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/type-2-diabetes-mellitus-model5981d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/renal-fibrosis-model.html</loc>
<image:image>
<image:title>Renal Fibrosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/renal-fibrosis-modelb87a4.jpg</image:loc>
</image:image>
<image:image>
<image:title>Renal Fibrosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/renal-fibrosis-modelb87a4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/immunosuppression-model.html</loc>
<image:image>
<image:title>Immunosuppression Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/immunosuppression-model9e95e.jpg</image:loc>
</image:image>
<image:image>
<image:title>Immunosuppression Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/immunosuppression-model9e95e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/clearpoint/convection-enhanced-delivery-ced-technology.html</loc>
<image:image>
<image:title>Convection-Enhanced Delivery (CED) Technology</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/convection-enhanced-delivery-ced-technology7e74b.png</image:loc>
</image:image>
<image:image>
<image:title>Convection-Enhanced Delivery (CED) Technology</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/convection-enhanced-delivery-ced-technology7e74b.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/clearpoint/nhp-neuroscience.html</loc>
<image:image>
<image:title>NHP Neuroscience</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nhp-neuroscience94a5c.jpg</image:loc>
</image:image>
<image:image>
<image:title>NHP Neuroscience</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nhp-neuroscience94a5c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/atopic-dermatitis-nhp-model.html</loc>
<image:image>
<image:title>Atopic Dermatitis NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/atopic-dermatitis-nhp-model0fc1f.jpg</image:loc>
</image:image>
<image:image>
<image:title>Atopic Dermatitis NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/atopic-dermatitis-nhp-model0fc1f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/pruritus-nhp-model.html</loc>
<image:image>
<image:title>Pruritus NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/pruritus-nhp-modelfcbdb.jpg</image:loc>
</image:image>
<image:image>
<image:title>Pruritus NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/pruritus-nhp-modelfcbdb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/inflammatory-bowel-disease-ibd-nhp-model.html</loc>
<image:image>
<image:title>Inflammatory Bowel Disease IBD NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/inflammatory-bowel-disease-ibd-nhp-model048b6.png</image:loc>
</image:image>
<image:image>
<image:title>Inflammatory Bowel Disease IBD NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/inflammatory-bowel-disease-ibd-nhp-model048b6.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/translation-research/targeted-organ-drug-delivery-platform-in-nhp.html</loc>
<image:image>
<image:title>Targeted Organ Drug Delivery Platform in NHP</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/targeted-organ-drug-delivery-platform-in-nhpe13f9.png</image:loc>
</image:image>
<image:image>
<image:title>Targeted Organ Drug Delivery Platform in NHP</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/targeted-organ-drug-delivery-platform-in-nhpe13f9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/aav-synuclein-overexpression-nhp-model.html</loc>
<image:image>
<image:title>AAV-α-Synuclein Overexpression NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/aav-synuclein-overexpression-nhp-model93460.jpg</image:loc>
</image:image>
<image:image>
<image:title>AAV-α-Synuclein Overexpression NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/aav-synuclein-overexpression-nhp-model93460.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/heart-failure-nhp-model.html</loc>
<image:image>
<image:title>Heart Failure NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/heart-failure-nhp-model8c759.jpg</image:loc>
</image:image>
<image:image>
<image:title>Heart Failure NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/heart-failure-nhp-model8c759.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/acute-lung-inflammation-ali-nhp-model.html</loc>
<image:image>
<image:title>Acute Lung Inflammation (ALI) NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/small/acute-lung-inflammation-ali-nhp-modelcce6e.png</image:loc>
</image:image>
<image:image>
<image:title>Acute Lung Inflammation (ALI) NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/page/acute-lung-inflammation-ali-nhp-modelcce6e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/pk-pd-adme/nose-to-brain-drug-delivery.html</loc>
<image:image>
<image:title>Nose-to-Brain Drug Delivery</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/nose-to-brain-drug-delivery15a9e.jpg</image:loc>
</image:image>
<image:image>
<image:title>Nose-to-Brain Drug Delivery</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/nose-to-brain-drug-delivery15a9e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/acute-hemorrhagic-shock-model-nhp-model.html</loc>
<image:image>
<image:title>Acute Hemorrhagic Shock Model NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/acute-hemorrhagic-shock-model-nhp-model5b827.png</image:loc>
</image:image>
<image:image>
<image:title>Acute Hemorrhagic Shock Model NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/acute-hemorrhagic-shock-model-nhp-model5b827.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/retinitis-pigmentosa-rp-nhp-model.html</loc>
<image:image>
<image:title>Retinitis Pigmentosa (RP) NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/retinitis-pigmentosa-rp-nhp-model49f0f.png</image:loc>
</image:image>
<image:image>
<image:title>Retinitis Pigmentosa (RP) NHP Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/retinitis-pigmentosa-rp-nhp-model49f0f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/nhp-pharmacology/liver-fibrosis-model.html</loc>
<image:image>
<image:title>Liver Fibrosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/small/liver-fibrosis-modelc2688.png</image:loc>
</image:image>
<image:image>
<image:title>Liver Fibrosis Model</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/liver-fibrosis-modelc2688.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/2025-recap-how-prisys-is-redefining-translati-17724118903612416.html</loc>
<image:image>
<image:title>Rückblick 2025: Wie Prisys die translationale Zuverlässigkeit in der NHP-Forschung neu definiert</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20260115105444c1b0c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-based-pharmacology-and-pharmacodynamic-17551261987906560.html</loc>
<image:image>
<image:title>NHP - basierte Pharmakologie und pharmakodynamische Dienste|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/meet-prisys-biotech-at-upcoming-eu-roadshow-17528791496221696.html</loc>
<image:image>
<image:title>Treffen Sie Prisys Biotech bei der kommenden EU Roadshow: September 2025</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025082013335410dba.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-2025-mid-year-review-17439743535129600.html</loc>
<image:image>
<image:title>Prisys Biotech-2025 Überprüfung der Mitte des Jahres</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/meet-prisys-in-2025-us-roadshow-17244423732487168.html</loc>
<image:image>
<image:title>Treffen Sie Prisys in der bevorstehenden US-Roadshow im März 2025</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-annual-report-2024-advancing-nhp-model-84009816.html</loc>
<image:image>
<image:title>PRISYS-Jahresbericht 2024: Weiterentwicklung von NHP-Modellen und präklinischer Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241204135917ca94f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-2024-q2-newsletter-77699729.html</loc>
<image:image>
<image:title>Prisys Biotech 2024 Q2 Newsletter – Verbesserte präklinische Forschung und Entwicklung für ZNS-Therapeutika mit kreuzreaktiven PRISYS-Modellen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240520124055bc2de.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/rtimri-for-parkinsons-disease-81120701.html</loc>
<image:image>
<image:title>Zielgerichtete Therapie der Parkinson-Krankheit: Durchbruch bei der MRT-gesteuerten Stammzelltransplantation in Echtzeit</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202409061001122b75a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/emotional-memory-chronic-pain-nhp-models-17724118815269888.html</loc>
<image:image>
<image:title>Wenn Schmerz zur Erinnerung wird: Emotionale Treiber chronischer Schmerzen und der Vorteil des NHP-Modells|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2026012713131077473.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/multi-endpoint-pain-assessment-the-future-17724118628574208.html</loc>
<image:image>
<image:title>Multi-Schmerzbewertung an mehreren Endpunkten: Die Zukunft der Entwicklung von Analgetika</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20260123153636bce28.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/analgesics-fail-in-preclinical-measure-pain-17724118707872768.html</loc>
<image:image>
<image:title>Warum scheitern so viele Analgetika in präklinischen Studien? Die Antwort liegt darin, wie wir Schmerzen messen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20260120155944a4ef1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/blood-sampling-time-point-in-pharmacokinetic-17724119089275904.html</loc>
<image:image>
<image:title>Design des Zeitpunkts der Blutentnahme in pharmakokinetischen (PK) Studien|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2026011316592151314.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pk-statistical-analysis-nca-parameters-guide-17724118803112960.html</loc>
<image:image>
<image:title>PK-Statistik: Parameter der nicht-kompartimentellen Analyse (NCA) und präklinische Anwendungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20260109161837141c9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-human-primate-models-are-critical-cns-17724118679151616.html</loc>
<image:image>
<image:title>Warum nicht-nichtmenschliche Primatenmodelle für ZNS-Oligonukleotidtherapeutika von entscheidender Bedeutung sind</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20260106130909b5b92.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/uric-acid-metabolism-in-humans-vs-monkeys-17724118661915648.html</loc>
<image:image>
<image:title>Harnsäurestoffwechsel beim Menschen vs. Affen: Translationale Implikationen für die Arzneimittelentwicklung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/2026010416213306463.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-human-primate-mash-associated-liver-fibros-17724118569706496.html</loc>
<image:image>
<image:title>Nicht-Menschliches Primaten-MASH-assoziiertes Leberfibrosemodell|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/p20251226155519da3af.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/imri-guided-brain-drug-delivery-17724118595576832.html</loc>
<image:image>
<image:title>Warum die IMRI-gesteuerte Medikamentenabgabe im Gehirn für eine präzise Zielausrichtung in NHP-Studien unerlässlich ist</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202512231619222564f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/ai-driven-markerless-3d-behavioral-analysis-17674260816552960.html</loc>
<image:image>
<image:title>KI-gesteuertes markerloses NHP 3D-Verhaltensanalysesystem|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202512181608129079f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/lps-induced-acute-lung-inflammation-ali-nhp-17674260965417984.html</loc>
<image:image>
<image:title>LPS-Induzierte akute Lungenentzündung (ALI) NHP-Modell|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202512161502375ccdb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/hdm-seb-induced-atopic-dermatitis-atd-model-17674260782834688.html</loc>
<image:image>
<image:title>HDM+SEB-Modell der induzierten atopischen Dermatitis (AtD) bei Javaneraffen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251212144449750c1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/one-to-multi-compartment-pk-models-17674261053891584.html</loc>
<image:image>
<image:title>PK-Modelle mit einem- bis mehreren-Kompartimenten erklärt|NHP-Pharmakokinetik|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251208140839d8db0.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-choose-a-reliable-preclinical-cro-key-17674260819780608.html</loc>
<image:image>
<image:title>So wählen Sie einen zuverlässigen präklinischen CRO aus|Schlüsselkriterien für Biotech-Unternehmen|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251204133731f364a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/translational-car-t-evaluation-in-vitro-17674260803085312.html</loc>
<image:image>
<image:title>Translationale CAR-T-Bewertung: In-vitro-Expertise und NHP-Studienunterstützung – Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202512011123451e873.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cns-drug-candidates-in-preclinical-study-17674260716364800.html</loc>
<image:image>
<image:title>Warum scheitern mehr als 90 % der ZNS-Arzneimittelkandidaten in klinischen Studien?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202511281410270841e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/parkinsons-disease-preclinical-models-17674281338971136.html</loc>
<image:image>
<image:title>Präklinische Modelle der Parkinson-Krankheit: Ein Leitfaden zur Auswahl von Neurotoxin-, genetischen und NHP-Modellen|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025112415472074828.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/high-precision-drug-delivery-and-ai-driven-nhp-17674260741432320.html</loc>
<image:image>
<image:title>Hoch-präzise Medikamentenverabreichung und KI-gesteuerte NHP-Translationsplattformen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025112108401436404.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/th17-driven-nhp-immunology-models-17625017679537152.html</loc>
<image:image>
<image:title>Th17-gesteuerte NHP-Immunologiemodelle|Translationale Autoimmunforschung bei Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251117110751844f3.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/ai-based-nhp-behavioratlas-system-3d-behavi-17625017234236416.html</loc>
<image:image>
<image:title>KI-basiertes NHP BehaviorAtlas®-System|3D-Verhaltensanalyseplattform|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251114162428314a9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/rfp-template-for-nhp-studies-17625017116222464.html</loc>
<image:image>
<image:title>RFP-Vorlage für NHP-Studien|Beschleunigen Sie die Effizienz der präklinischen Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025111015483953c4b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cold-allodynia-pain-model-in-cynomolgus-monkey-17625017538438144.html</loc>
<image:image>
<image:title>Kaltes Allodynie-Schmerzmodell bei Cynomolgus-Affen|Prisys Biotechnologies</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251107160515acddb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/mri-guided-intracerebral-drug-delivery-17625017174320128.html</loc>
<image:image>
<image:title>MRT-Plattform für die gesteuerte intrazerebrale Medikamentenverabreichung|Prisys Biotech ZNS-Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025110514460235db1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-respiratory-disease-models-and-airway-drug-17625017281373184.html</loc>
<image:image>
<image:title>NHP-Modelle für Atemwegserkrankungen und Plattform zur Verabreichung von Atemwegsmedikamenten|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251028164336adaf3.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-renal-biopsy-17625017221702656.html</loc>
<image:image>
<image:title>NHP-Plattform für Nierenbiopsie und Modelle für Nierenerkrankungen|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251022172158e338d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pk-study-targeted-drug-delivery-17625017214346240.html</loc>
<image:image>
<image:title>PK-Studien und gezielte Arzneimittelabgabe|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202510171638300dafe.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-ai-based-behavioral-analysis-17625017142699008.html</loc>
<image:image>
<image:title>NHP-Forschungs- und KI-basierte Verhaltensanalyseplattform von Prisys Biotechnologies</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025101517485012ee9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nasal-to-brain-n2b-delivery-technology-for-c-17625017553855488.html</loc>
<image:image>
<image:title>Technologie zur Verabreichung von Nasal-zu-Gehirn (N2B) für die ZNS-Forschung|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20251011133522c7c7b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/shr-2004-a-breakthrough-in-vte-prevention-for-17625017297789952.html</loc>
<image:image>
<image:title>SHR-2004: Ein Durchbruch in der VTE-Prävention für Patientinnen mit Eierstockkrebs – eine Erfolgsgeschichte von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025101011280623985.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-rhesus-monkey-models-prisys-bio-17537836520514560.html</loc>
<image:image>
<image:title>Cynomolgus &amp; Rhesus Monkey -Modelle|Prisys Biotech Präklinischer Cro</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202509191421539fa9b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/idiopathic-pulmonary-fibrosis-ipf-nhp-model-17528791373276160.html</loc>
<image:image>
<image:title>Idiopathische Lungenfibrose (IPF) NHP -Modell|Prisys Biotech Präklinischer Cro</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250912151948fd2c4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-monkey-biodistribution-study-17528791544931328.html</loc>
<image:image>
<image:title>Cynomolgus Monkey BioDiTItribution Studies|Prisys Biotech Präklinischer Cro</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202509091635226f118.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-models-for-hematology-and-stroke-17528791598375936.html</loc>
<image:image>
<image:title>Prisys Biotech NHP -Modelle für Hämatologie und Schlaganfallforschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250903101944cac91.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-importance-of-administration-volume-17528791427589120.html</loc>
<image:image>
<image:title>Die Bedeutung des Verwaltungsvolumens in präklinischen Studien|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202508261427201a2af.gif</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/brain-targeted-drug-delivery-17528791358153728.html</loc>
<image:image>
<image:title>Brain - Zieldedikamentsabgabe|Prisys Biotech Präklinischer NHP -Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202508221539309f4a5.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/adc-drug-development-translational-pk-pd-fra-17528791425852416.html</loc>
<image:image>
<image:title>ADC Drug Development|Translational PK/PD -Framework in präklinischen NHP -Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025081814020269ffa.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-pain-models-for-translational-drug-discove-17493755777639424.html</loc>
<image:image>
<image:title>NHP -Schmerzmodelle für translationale Arzneimittelentdeckungen|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250813095806db594.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/serum-vs-plasma-choosing-the-optimal-matrix-17493755780195328.html</loc>
<image:image>
<image:title>Serum vs. Plasma: Auswahl der optimalen Matrix für präklinische Bioanalyse</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250805095551af23f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/preclinical-dosing-guidelines-iv-po-volume-17493755748180992.html</loc>
<image:image>
<image:title>Präklinische Dosierungsrichtlinien: IV &amp; PO Volumen, pH und Osmolarität für genaue PK in NHPs und anderen Arten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250731153850aa43a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-copd-model-17493755950769152.html</loc>
<image:image>
<image:title>Top COPD -Forschungsmodelle und Atemplattform Exzellenz von Prisys</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250730125053bd455.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-acute-hemorrhage-model-17493755733271552.html</loc>
<image:image>
<image:title>NHP akute Blutungsmodell: Ein entscheidendes Instrument zur Beschleunigung neuer hämatologischer Arzneimittelentwicklung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250722163908bd854.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pruritus-research-il-31-nhp-itch-model-17493756445975552.html</loc>
<image:image>
<image:title>Pruritus-Forschung: PRISYS Biotechs IL-31-induziertes NHP-Modell zur Bewertung von Anti-Therapien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202504011023488ec4a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/a-guide-to-anti-drug-antibody-ada-assessment-17439744210772992.html</loc>
<image:image>
<image:title>Ein Leitfaden zur Bewertung der Anti-Drogen-Antikörper (ADA)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025071015011851653.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/respiratory-therapies-prisys-biotech-s-integr-17439743712125952.html</loc>
<image:image>
<image:title>Atemtherapien: Integrierte NHP -Plattform von Prisys Biotech für die präklinische Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202507080951326501f.gif</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-pain-models-accelerating-analgesic-drug-d-17439743791211520.html</loc>
<image:image>
<image:title>NHP -Schmerzmodelle: Beschleunigung der Analgetikumentwicklung bei Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/p20250704135241befde.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-model-platforms-to-support-drug-developmen-17439743729345536.html</loc>
<image:image>
<image:title>NHP -Modellplattformen zur Unterstützung der Arzneimittelentwicklung bei komplexen Krankheiten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250123123328c619c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/key-considerations-for-dosing-volume-17439743669724160.html</loc>
<image:image>
<image:title>Wichtige Überlegungen für Dosierungsvolumen, pH und Formulierungen in Tiermodellen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202506260936191360e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/engineered-exosomes-revolutionizing-drug-deli-17439743739438080.html</loc>
<image:image>
<image:title>Technische Exosomen: Revolutionierung der Arzneimittelabgabe bei ZNS -Störungen - Präklinische Erkenntnisse aus Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250617131838d8cea.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/guiding-principles-for-animal-species-selectio-17439743526708224.html</loc>
<image:image>
<image:title>Leitprinzipien für die Selektion von Tierarten in Nukleinsäure -Arzneimittel -toxikologischen Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202506131705069d4cc.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-s-advanced-dsa-and-imri-for-hem-17439743689712640.html</loc>
<image:image>
<image:title>Die fortgeschrittene DSA und IMRI von Prisys Biotech für hämatologische, vaskuläre und Nierenerkrankungen Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250610100231b6146.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-monkey-pain-models-17439743582725120.html</loc>
<image:image>
<image:title>Cynomolgus -Affenschmerzmodelle: Antrieb der translationalen Forschung für Durchbruch -Ion -Kanal -Therapeutika</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250605125053411da.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancing-atopic-dermatitis-research-prisys-b-17439744790275072.html</loc>
<image:image>
<image:title>Vorrückung bei atopischer Dermatitisforschung: PRISYS Biotechs Non-Human Primate (NHP) Modell</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250530142432192c3.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-s-nhp-atopic-dermatitis-model-f-17439743431205888.html</loc>
<image:image>
<image:title>PRISYS Biotechs NHP atopic Dermatitismodell für die Entwicklung anti-pruritischer Arzneimittel</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/p20250527155048d3f8c.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/designing-animal-studies-key-considerations-f-17381750620136448.html</loc>
<image:image>
<image:title>Gestaltung von Tierstudien: Schlüsselüberlegungen zum präklinischen Forschungserfolg</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025052317011698995.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/atopic-dermatitis-how-cynomolgus-monkey-model-17381750320161792.html</loc>
<image:image>
<image:title>Atopische Dermatitis: Wie Cynomolgus -Affenmodelle die Präzisionstherapeutika vorantreiben</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025052012503626be2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/asthma-research-why-non-human-primate-models-17381750402556928.html</loc>
<image:image>
<image:title>Asthmaforschung: Warum nichtmenschliche Primatenmodelle für neuartige Arzneimittelentwicklung entscheidend sind</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250512174400b2bec.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/aso-pharmacokinetics-absorption-17381750350504960.html</loc>
<image:image>
<image:title>Verständnis von Antisense -Oligonukleotid (ASO) Pharmakokinetik: Schlüsselfaktoren bei Absorption und Verteilung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202505081658273697e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-inhalation-studies-for-biologics-prisys-17381750760236032.html</loc>
<image:image>
<image:title>NHP -Inhalationsstudien für Biologika: Prisys 'spezialisierte präklinische CRO -Dienste</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025043015244899508.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advanced-preclinical-inhalation-studies-techn-17381750390203392.html</loc>
<image:image>
<image:title>Fortgeschrittene präklinische Inhalationsstudien: Technische Fähigkeiten und Fachkenntnisse bei Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202504291646054725d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetics-pk-key-parameters-17381750274122752.html</loc>
<image:image>
<image:title>Verständnis der Pharmakokinetik (PK): Schlüsselparameter und Anwendungen in der Arzneimittelentwicklung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025042511302920eb4.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/intracerebroventricular-icv-injection-17381788874138624.html</loc>
<image:image>
<image:title>Intracerebroventrikuläre (ICV) Injektion: Präzisions -ZNS -Abgabe für die präklinische Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025042210212390d49.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/intracerebral-icm-injection-precision-targe-17381750317884416.html</loc>
<image:image>
<image:title>Intracerebral (ICM) Injektion: Präzisionsziel für ZNS -Therapeutika - Präklinische Überlegungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202504180938433bda1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/intrathecal-it-injection-a-direct-cns-deliv-17381750231426048.html</loc>
<image:image>
<image:title>Intrathekale (IT) Injektion: Ein direkter ZNS -Route für fortgeschrittene Therapien - Präklinische Überlegungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202504160948404ad29.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancing-parkinson-s-disease-research-with-th-17381750244287488.html</loc>
<image:image>
<image:title>Förderung der Parkinson -Krankheitsforschung mit dem NHP -Modell</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202504111626379b25c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/preclinical-pk-pd-studies-nhp-models-17381750614582272.html</loc>
<image:image>
<image:title>Präklinische PK/PD -Studien &amp; NHP -Modelle für die Arzneimittelentwicklung|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025040809451573e94.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/targeting-interleukin-31-autoimmune-disease-17300025288795136.html</loc>
<image:image>
<image:title>Targeting Interleukin -31 (il -31): Eine neuartige Grenze zur Entwicklung von Autoimmunerkrankungen - Prisys Biotech NHP -Modelle für präklinische Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202504011023488ec4a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nonclinical-immunotoxicity-assessment-strateg-17295714858673152.html</loc>
<image:image>
<image:title>Nichtklinische Bewertung der Immunotoxizität: Strategie, wichtige Überlegungen und Methodenauswahl</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/232.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/microbial-testing-and-its-impact-on-nhp-17295714642076672.html</loc>
<image:image>
<image:title>Mikrobielle Tests und deren Auswirkungen auf nichtmenschliche Primaten in präklinischen DMPK-Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250325170337bc1d3.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-monkey-endometriosis-model-17295714845991936.html</loc>
<image:image>
<image:title>Cynomolgus Monkey Endometriose -Modell zur Förderung der therapeutischen Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025032013423376e5c.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/membranous-nephropathy-model-17295714588075008.html</loc>
<image:image>
<image:title>Vorrückung der membranösen Nephropathie (MN) Arzneimittelentwicklung: Prisys Biotechs Cynomolgus Monkey Model Plattform</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/148.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetics-of-inhaled-drugs-17295714785813504.html</loc>
<image:image>
<image:title>Pharmakokinetik von inhalierten Arzneimitteln: eine Paradigmenverschiebung von systemisch zu Lungenexposition</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250310174924e6965.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/animal-models-for-womens-health-17295714557535232.html</loc>
<image:image>
<image:title>PRISYS BIOTECH: Tiermodelle für Frauengesundheitstherapeutika</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202503071009566b10b.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/world-obesity-day-nhp-metabolic-models-17295748878164992.html</loc>
<image:image>
<image:title>Weltverzögertag|PRISYS Biotech NHP-Stoffwechselmodelle: Stromversorgung der Entwicklung von Anti-Adipositas-Therapien der nächsten Generation</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025030417050873614.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-s-cynomolgus-monkey-psoriasis-m-17295748506543104.html</loc>
<image:image>
<image:title>PRISYS Biotechs Cynomolgus Monkey Psoriasis -Modell: Vorrückung der präklinischen Pharmakodynamikbewertung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202502280925537e8ce.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/liver-biopsy-a-crucial-technique-in-large-ani-17295715009553408.html</loc>
<image:image>
<image:title>Leberbiopsie: Eine entscheidende Technik in großen pharmakokinetischen (PK) -Studien für neue Arzneimittelentwicklung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025022509490064708.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/integration-of-pharmacokinetics-and-pharmacody-17295714607948800.html</loc>
<image:image>
<image:title>Integration von Pharmakokinetik und Pharmakodynamik in die Arzneimittelentwicklung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025022110272438f73.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/what-does-proof-of-concept-poc-in-drug-devel-17295715059573760.html</loc>
<image:image>
<image:title>Was bestätigt Proof of Concept (POC) in der Arzneimittelentwicklung wirklich?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250218092412fb5f5.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/animal-models-challenges-and-applications-in-17295714519114752.html</loc>
<image:image>
<image:title>Tiermodelle|Herausforderungen und Anwendungen in der Entwicklung des Schmerzmodells</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202502141328261a025.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nonclinical-pharmacodynamic-research-17295714955387904.html</loc>
<image:image>
<image:title>Nichtklinische pharmakodynamische Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2025021214305230811.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/selecting-the-ideal-non-human-primate-for-toxi-17244424248452096.html</loc>
<image:image>
<image:title>Auswählen des idealen nichtmenschlichen Primaten für toxikologische Studien: Cynomolgus-Makaken, Rhesus-Makaque und Marmoset</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250205142604591d8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/systemic-lupus-erythematosus-sle-and-the-rol-17295714592793600.html</loc>
<image:image>
<image:title>Systemischer Lupus erythematodes (SLE) und die Rolle von Tiermodellen bei der therapeutischen Entwicklung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250121104603461db.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-human-primate-model-for-rheumatoid-arthrit-17295714604770304.html</loc>
<image:image>
<image:title>Nichtmenschlicher Primatenmodell für rheumatoide Arthritis (RA)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250117153412b3280.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/animal-brain-stereotactic-instruments-17295714532860928.html</loc>
<image:image>
<image:title>Stereotaktische Instrumente des Tierhirns basierend auf 3D -Koordinatensystemen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250115133928772c1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/animal-models-for-in-vivo-testing-1-establi-17295715106595840.html</loc>
<image:image>
<image:title>Tiermodelle für In -vivo -Tests (1): Einrichtung und Klassifizierung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250112202508b936b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/potential-routes-for-biologics-to-brain-84009798.html</loc>
<image:image>
<image:title>Erforschung potenzieller Wege für Biologika, in das Gehirn einzudringen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202501071034417382f.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancing-rheumatoid-arthritis-ra-research-w-84009793.html</loc>
<image:image>
<image:title>Weiterentwicklung der Forschung zu rheumatoider Arthritis (RA) mit nichtmenschlichen Primatenmodellen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20250102143547c190f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/animal-models-for-atopic-dermatitis-84009799.html</loc>
<image:image>
<image:title>Erforschung der Wirksamkeit von Arzneimitteln gegen atopische Dermatitis in Tiermodellen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202412301624286dab0.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-critical-role-of-animal-models-in-human-di-84009794.html</loc>
<image:image>
<image:title>Die entscheidende Rolle von Tiermodellen in der Erforschung menschlicher Krankheiten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202412271723592a539.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/parkin-gene-deficiency-monkey-model-reveals-ne-84009837.html</loc>
<image:image>
<image:title>Parkin-Gen-Mangel-Affenmodell enthüllt neue Mechanismen und therapeutische Ziele für die Parkinson-Krankheit</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241224162504c3c54.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nonclinical-drug-development-guide-toxicity-84009795.html</loc>
<image:image>
<image:title>Leitfaden zur nichtklinischen Arzneimittelentwicklung: Studien zur akuten, subakuten, subchronischen und chronischen allgemeinen Toxizität</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241220112548bfcff.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nasal-to-brain-n2b-drug-delivery-84009808.html</loc>
<image:image>
<image:title>Innovative Medikamentenabgabe über die Nase ins Gehirn (N2B): Umgehung der Blut-Hirn-Schranke</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202412161319158371d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/minipig-as-nonclinical-large-animal-84009796.html</loc>
<image:image>
<image:title>Chancen und Herausforderungen von Minischweinen als nichtklinische Großtierart</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024120911110171c55.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/drug-delivery-strategies-for-brain-diseases-83010933.html</loc>
<image:image>
<image:title>Strategien zur Arzneimittelabgabe bei Hirnerkrankungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202412030944155b417.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/real-time-intraoperative-mri-navigation-suppo-82988226.html</loc>
<image:image>
<image:title>Intraoperative MRT-Navigation in Echtzeit: Unterstützung der FDA-Zulassung der ersten Gentherapie für AADC-Mangel</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202411280914044b8c7.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/ocular-toxicity-studies-of-eye-drops-drug-exp-82996165.html</loc>
<image:image>
<image:title>Studien zur Augentoxizität von Augentropfen: Arzneimittelexposition und Sicherheitsbewertung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241126163322d869c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-establishes-cynomolgus-monkey-p-82654045.html</loc>
<image:image>
<image:title>Prisys Biotech etabliert ein Cynomolgus-Affen-Psoriasis-Modell, um die Arzneimittelentwicklung zu beschleunigen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024111910582749e02.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/comprehensive-non-human-primate-models-for-ren-82654374.html</loc>
<image:image>
<image:title>Umfassende nichtmenschliche Primatenmodelle für die Erforschung von Nierenerkrankungen von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024111511090891eb1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/comprehensive-preclinical-safety-evaluation-of-82654044.html</loc>
<image:image>
<image:title>Umfassende präklinische Sicherheitsbewertung von Antikörper-Wirkstoff-Konjugaten (ADCs) bei nichtmenschlichen Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241111141121c84f3.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetics-evaluation-of-antibody-drug-c-82654043.html</loc>
<image:image>
<image:title>Pharmakokinetische Bewertung von Antikörper-Wirkstoff-Konjugaten (ADCs) in nichtmenschlichen Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202411081401283f377.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacodynamics-evaluation-of-adcs-82654040.html</loc>
<image:image>
<image:title>Pharmakodynamische Bewertung von ADCs</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241106161502bd911.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/understanding-the-dmpk-of-adc-drugs-82654041.html</loc>
<image:image>
<image:title>Den DMPK von ADC-Medikamenten verstehen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241029101148c4fbd.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/progress-in-the-development-of-nucleic-acid-dr-82654051.html</loc>
<image:image>
<image:title>Fortschritte bei der Entwicklung von Nukleinsäure-Medikamenten und den Forschungskapazitäten von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024101713330113621.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advances-in-mrna-pulmonary-delivery-systems-an-82395243.html</loc>
<image:image>
<image:title>Fortschritte bei mRNA-Lungenabgabesystemen und den innovativen Dienstleistungen von Prisys biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241014090616a9ff8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/2024-nobel-prize-in-physiology-or-medicine-82654067.html</loc>
<image:image>
<image:title>Warum wurde der Nobelpreis für Physiologie oder Medizin 2024 an diese beiden Wissenschaftler verliehen, die MicroRNA untersuchten?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20241008113621e90e6.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetic-pk-considerations-for-centra-82654064.html</loc>
<image:image>
<image:title>Überlegungen zur Pharmakokinetik (PK) für Arzneimittel des Zentralnervensystems (ZNS).</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024092913295797d3f.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancements-in-cns-research-ced-imri-79656476.html</loc>
<image:image>
<image:title>Fortschritte in der ZNS-Forschung: MRI-kompatibles Gehirninjektionssystem und CED-Technologie von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408062147375802b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-monkey-mcao-model-81120696.html</loc>
<image:image>
<image:title>Förderung therapeutischer Innovationen bei Blutungen und Blutgerinnseln mit dem MCAO-Modell des Javaneraffen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202409241700121ed48.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/dmpk-evaluation-of-central-nervous-system-cns-81120693.html</loc>
<image:image>
<image:title>DMPK-Bewertung von Arzneimitteln für das zentrale Nervensystem (ZNS)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240924110059a8fdd.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/animal-models-of-human-diseases-81120688.html</loc>
<image:image>
<image:title>Tiermodelle für menschliche Krankheiten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240920153353a85bd.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/innovations-in-pain-evaluation-ai-driven-beha-81120690.html</loc>
<image:image>
<image:title>Innovationen in der Schmerzdiagnostik: KI-gestützte Verhaltensanalyse</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024091816220958caa.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/china-experimental-monkey-industry-81120694.html</loc>
<image:image>
<image:title>Geschichte, aktueller Status, Herausforderungen und Chancen der experimentellen Affenindustrie Chinas</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240909130237c0dc8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/human-disease-animal-models-81120687.html</loc>
<image:image>
<image:title>Tiermodelle für menschliche Krankheiten: Ein entscheidendes Instrument zur Förderung der biomedizinischen Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240904101437e1414.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-importance-of-preclinical-pharmacodynamics-81120700.html</loc>
<image:image>
<image:title>Die Bedeutung der präklinischen Pharmakodynamik in der Arzneimittelentwicklung|Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408281439443e4db.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/intranasal-administration-in-animal-studies-81120699.html</loc>
<image:image>
<image:title>Intranasale Verabreichung in Tierstudien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240827104336fadf5.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/revolutionizing-cns-drug-development-prisys-b-79410748.html</loc>
<image:image>
<image:title>Revolutionierung der Entwicklung von ZNS-Medikamenten: PRISYS Biotech stellt IMRI-Technologie vor</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240729151529d56e9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/convection-enhanced-delivery-81120695.html</loc>
<image:image>
<image:title>Fortschritte in der Präzisionsmedizin: Convection-Enhanced Delivery (CED)-Technologie von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240822125521f1687.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-monkey-chronic-kidney-disease-model-81120698.html</loc>
<image:image>
<image:title>Modell der chronischen Nierenerkrankung (CKD) bei Cynomolgus-Affen von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240820104326c1ab2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nonclinical-safety-evaluation-of-ocular-drug-d-79528733.html</loc>
<image:image>
<image:title>Nichtklinische Sicherheitsbewertung der okulären Arzneimittelabgabe unter Verwendung von Cynomolgus-Makaken</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080116325669291.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/compartment-pk-model-81120702.html</loc>
<image:image>
<image:title>Kompartiment- und Nicht-Kompartimentmodelle in der Pharmakokinetik verstehen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408121135341dcc9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-role-of-aav-in-gene-therapy-immune-respon-79528737.html</loc>
<image:image>
<image:title>Die Rolle von AAV in der Gentherapie: Immunreaktionen und Toxizität</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801163452493e1.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advanced-cns-delivery-techniques-in-cynomolgus-81120691.html</loc>
<image:image>
<image:title>Fortschrittliche Verabreichungstechniken für das ZNS bei Javaneraffen: Beschleunigung der Entwicklung von Oligonukleotid-Medikamenten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240809165539b61ef.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/optimized-nonclinical-immunogenicity-evaluatio-79528734.html</loc>
<image:image>
<image:title>Optimierte nichtklinische Strategien zur Bewertung der Immunogenität</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080116353273f4d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/reducing-the-use-of-nonhuman-primates-in-noncl-79528751.html</loc>
<image:image>
<image:title>Reduzierung der Verwendung nichtmenschlicher Primaten in nichtklinischen Sicherheitsbewertungen: Perspektiven der FDA und der Industrie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801163624dabc0.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/lcms-preclinical-bioanalysis-of-lnp-based-gene-79528764.html</loc>
<image:image>
<image:title>LCMS Präklinische Bioanalyse von LNP-basierten Gentherapiemedikamenten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801181230b6a27.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/mrna-based-therapies-past-79528766.html</loc>
<image:image>
<image:title>MRNA-basierte Therapien: Vergangenheit</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080118112364d2d.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pk-strategies-of-pdc-79528730.html</loc>
<image:image>
<image:title>Strategien zur pharmakokinetischen Untersuchung von Peptid-Wirkstoff-Konjugaten (PDCs)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080109123097cb8.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacodynamic-pd-evaluation-of-gene-therap-79528762.html</loc>
<image:image>
<image:title>Pharmakodynamische (PD) Bewertung der Gentherapie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801180623d1663.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetics-and-bioanalysis-of-oligonucle-79528757.html</loc>
<image:image>
<image:title>Pharmakokinetik und Bioanalyse von Oligonukleotid-Arzneimitteln-(1)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801180452c5c2a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetics-and-bioanalysis-of-oligonucle-79528770.html</loc>
<image:image>
<image:title>Pharmakokinetik und Bioanalyse von Oligonukleotid-Arzneimitteln: Absorptions- und Plasmapharmakokinetik (PK)-Eigenschaften</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801180317bc744.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/factors-to-consider-for-the-immunogenicity-of-79528763.html</loc>
<image:image>
<image:title>Zu berücksichtigende Faktoren für die Immunogenität von Oligonukleotid-Medikamenten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011801502cfb9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/mrna-a-powerful-and-versatile-tool-for-fighti-79528775.html</loc>
<image:image>
<image:title>MRNA: Ein leistungsstarkes und vielseitiges Mittel zur Bekämpfung von Krankheiten - Prisys-Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011756272a013.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/chinese-scientists-offers-new-strategies-to-re-79528746.html</loc>
<image:image>
<image:title>Chinesische Wissenschaftler bieten neue Strategien zur Umkehrung der Kernsymptome der Parkinson-Krankheit an</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801175516ecb8a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotechnology-novel-lipid-nanoparticle-79528743.html</loc>
<image:image>
<image:title>Prisys Biotechnology: Neuartige Lipid-Nanopartikel für den mRNA-Transport bei Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117542971a31.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-importance-of-translational-medicine-resea-79528755.html</loc>
<image:image>
<image:title>Die Bedeutung der translationalen Medizinforschung von der Grundlagenforschung bis zu klinischen Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801175156b8ed0.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-main-factors-considered-in-woe-analysis-79528760.html</loc>
<image:image>
<image:title>Die wichtigsten Faktoren, die bei der WOE-Analyse berücksichtigt werden</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801175020842f8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-deliver-biologics-to-the-brain-79528761.html</loc>
<image:image>
<image:title>Wie gelangen Biologika ins Gehirn?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801174910a58bb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-drugs-move-and-change-in-our-bodies-a-bri-79528749.html</loc>
<image:image>
<image:title>Wie sich Arzneimittel in unserem Körper bewegen und verändern: Eine kurze Einführung in die Pharmakokinetik</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011748076fca9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-develop-new-drugs-faster-and-safer-a-g-79528750.html</loc>
<image:image>
<image:title>So entwickeln Sie neue Medikamente schneller und sicherer: Ein Leitfaden für präklinische DMPK-Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117445005c7b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/group-housing-guidelines-for-laboratory-monkey-79528747.html</loc>
<image:image>
<image:title>Richtlinien zur Gruppenunterbringung von Laboraffen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117440822f67.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-vital-role-of-experimental-monkeys-in-adva-79528742.html</loc>
<image:image>
<image:title>Die entscheidende Rolle von Versuchsaffen bei der Weiterentwicklung der wissenschaftlichen Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801174211d2a1b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/understanding-macaca-fascicularis-cynomolgus-79528758.html</loc>
<image:image>
<image:title>Macaca Fascicularis (Cynomolgus-Affe) verstehen: Schlüsselmerkmale und Beiträge zur biomedizinischen Forschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801174043f9c14.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/revolutionizing-metabolic-disease-treatment-a-79528752.html</loc>
<image:image>
<image:title>Revolutionierung der Behandlung von Stoffwechselerkrankungen: Fortschritte und Herausforderungen in der Entwicklung von Peptidmedikamenten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117395084c9b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-evaluate-the-safety-of-skin-products-be-79528740.html</loc>
<image:image>
<image:title>Wie lässt sich die Sicherheit von Hautpflegeprodukten vor klinischen Studien bewerten?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801173853b9e8e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-significant-role-of-experimental-monkeys-i-79528765.html</loc>
<image:image>
<image:title>Die bedeutende Rolle von Versuchsaffen bei der Entwicklung innovativer Medikamente: Ein Blick hinter die Kulissen des Geschäfts</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801173640dbcdb.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/liver-toxicity-as-a-key-concern-for-sirna-drug-79528759.html</loc>
<image:image>
<image:title>Lebertoxizität als Hauptproblem bei SiRNA-Medikamenten: Eine umfassende Analyse Zielspezifität: Das zweischneidige Schwert der SiRNA</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801173252513ea.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancing-sirna-therapeutics-overcoming-chall-79528732.html</loc>
<image:image>
<image:title>Weiterentwicklung der SiRNA-Therapeutika: Herausforderungen bei der Arzneimittelentwicklung bewältigen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117311060b15.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/application-prospects-of-gene-drugs-based-on-l-79528738.html</loc>
<image:image>
<image:title>Anwendungsaussichten von Genmedikamenten auf Basis von Lipidnanopartikeln</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801172808b0a45.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/key-points-in-designing-strategies-for-non-79528748.html</loc>
<image:image>
<image:title>Wichtige Punkte bei der Entwicklung von Strategien für nichtklinische Studien an Jungtieren</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801172702f375a.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/insight-into-the-sensory-and-behavioral-traits-79528771.html</loc>
<image:image>
<image:title>Einblicke in die sensorischen und verhaltensbezogenen Merkmale nichtmenschlicher Primaten (NHPs)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117261321519.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nonclinical-study-evaluation-q-a-79528754.html</loc>
<image:image>
<image:title>Fragen und Antworten zur nichtklinischen Studienbewertung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801172429e1895.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/significance-principles-and-requirements-of-79528767.html</loc>
<image:image>
<image:title>Bedeutung, Grundsätze und Anforderungen der Sicherheitspharmakologieforschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117231644f61.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-evaluate-preclinical-pharmacological-ef-79528741.html</loc>
<image:image>
<image:title>Wie lässt sich die präklinische pharmakologische Wirksamkeit bewerten?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801172217a2b22.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/reflections-on-non-clinical-pharmacology-studi-79528735.html</loc>
<image:image>
<image:title>Überlegungen zu nichtklinischen pharmakologischen Studien und Bewertung von Therapeutika für nichtalkoholische Steatohepatitis (NASH)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011720005c93e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancing-cns-and-cgt-research-prisys-biotech-79528729.html</loc>
<image:image>
<image:title>Förderung der ZNS- und CGT-Forschung: Prisys Biotechnologies ist führend</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011718404c246.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-human-primate-cerebrospinal-fluid-collecti-79528739.html</loc>
<image:image>
<image:title>Richtlinien zur Entnahme von Zerebrospinalflüssigkeit bei nichtmenschlichen Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801171318f7961.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/considerations-for-interpreting-clinical-patho-79528736.html</loc>
<image:image>
<image:title>Überlegungen zur Interpretation klinischer Pathologiedaten bei nichtmenschlichen Primaten (NHPs) und Hunden</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117122736428.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/integrating-cns-safety-evaluation-into-79528727.html</loc>
<image:image>
<image:title>​​​​​​​Integration der ZNS-Sicherheitsbewertung in allgemeine toxikologische Studien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080117110558056.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-conduct-preclinical-pharmacology-toxico-79528769.html</loc>
<image:image>
<image:title>Wie führt man eine präklinische pharmakologische/toxikologische Bewertung von ADCs durch?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801170828e5c98.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/adme-insights-for-oligonucleotide-drugs-79529352.html</loc>
<image:image>
<image:title>ADME Insights für Oligonukleotid-Medikamente (1) - Absorption, Verteilung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011705192b402.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/adme-insights-for-oligonucleotide-drugs-79528745.html</loc>
<image:image>
<image:title>ADME Insights für Oligonukleotid-Medikamente (2) - Stoffwechsel und Ausscheidung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801164818e22a4.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/preclinical-animal-studies-1-animal-specie-79528728.html</loc>
<image:image>
<image:title>Präklinische Tierstudien (1) - Tierarten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011646162c426.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/clinical-pathology-data-interpretation-challen-79528753.html</loc>
<image:image>
<image:title>Herausforderungen und Strategien bei der Interpretation klinisch-pathologischer Daten in präklinischen Studien an Hunden und nichtmenschlichen Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801164503e9bd9.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/preclinical-animal-studies-2-routes-and-vo-79528772.html</loc>
<image:image>
<image:title>Präklinische Tierstudien (2) - Verabreichungswege und -volumina</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240801163712d0df1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/mrna-based-therapies-present-79528774.html</loc>
<image:image>
<image:title>MRNA-basierte Therapien: Gegenwart</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080118104113739.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/mrna-based-therapies-future-and-challenges-79528773.html</loc>
<image:image>
<image:title>MRNA-basierte Therapien: Zukunft und Herausforderungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024080118092133eb2.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/brief-introduction-about-biological-analysis-o-79528768.html</loc>
<image:image>
<image:title>Kurze Einführung zur biologischen Analyse der Gentherapie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202408011807079dc4e.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/cynomolgus-monkey-in-ophthalmic-drug-research-79410749.html</loc>
<image:image>
<image:title>Cynomolgus-Affe in der Augenheilmittelforschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024072509180742b12.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-nhp-models-immunology-inflammatio-79410750.html</loc>
<image:image>
<image:title>Translationale und kreuzreaktive Studien mit den NHP-Modellen für Immunologie und Entzündung von Prisys</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024072212200879ff1.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-na-ve-nhps-in-preclinical-trials-a-cost-e-79190822.html</loc>
<image:image>
<image:title>Nicht-naive NHPs in präklinischen Studien: Eine kostengünstige Lösung von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024071618013071b40.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-asthma-model-79190806.html</loc>
<image:image>
<image:title>NHP-Asthmamodell: Unterstützung präklinischer Studien zur Arzneimittelwirksamkeit mit Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202407051359254acc6.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/advancing-immunology-and-inflammation-research-79190808.html</loc>
<image:image>
<image:title>Förderung der Immunologie- und Entzündungsforschung mit Javaneraffen-Modellen - Prisys Biotechnologies</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240703110911ef80e.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/direct-delivery-of-oligonucleotide-drugs-to-th-79190803.html</loc>
<image:image>
<image:title>Direkte Abgabe von Oligonukleotid-Arzneimitteln an das ZNS und häufige histopathologische Veränderungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202406131052303d31d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/intra-cerebrovascular-stroke-ich-model-prisys-79190805.html</loc>
<image:image>
<image:title>Intracerebrovaskuläres Schlaganfallmodell (ICH) von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240607164926587f9.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-clinical-pharmacodynamics-research-an-ess-75161045.html</loc>
<image:image>
<image:title>Nichtklinische Pharmakodynamikforschung: Ein wesentlicher Aspekt bei der Entwicklung von SiRNA-Medikamenten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202402211320123fe5b.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/mri-guided-large-animal-central-nervous-system-77699726.html</loc>
<image:image>
<image:title>MRT-gesteuertes Präzisionslokalisierungs- und -abgabesystem für das zentrale Nervensystem von Großtieren geht an Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024042910594482ea8.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/innovative-solutions-for-advancing-respiratory-77052036.html</loc>
<image:image>
<image:title>Innovative Lösungen zur Weiterentwicklung der Atemwegstherapie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202404261311431ebfc.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-advancing-animal-experimentation-throu-74783065.html</loc>
<image:image>
<image:title>Prisys: Tierversuche durch Cynomolgus-Makaken-Studien vorantreiben</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202402271423376ec81.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-achieves-full-accreditation-from-aaalac-76173795.html</loc>
<image:image>
<image:title>Prisys erhält vollständige Akkreditierung von AAALAC International: ein Meilenstein bei der Gewährleistung hoher Standards der Labortierpflege.</image:title>
<image:loc>https://img01.v15cdn.com/gallery/4x3/265.webp</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/elevating-nucleic-acid-therapeutics-through-cu-74654643.html</loc>
<image:image>
<image:title>Nukleinsäure-Therapeutika auf dem neuesten Stand bringen – mit nichtmenschlichen Primatenmodellen von Prisys Biotech</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202401261332041ba3c.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/revolutionizing-cns-drug-delivery-prisys-and-74125623.html</loc>
<image:image>
<image:title>Revolutionierung der Medikamentenverabreichung im ZNS: Prisys und das Versprechen der intrathekalen Injektion</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240111101138bd6a1.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nonhuman-primate-study-newsletter-2024-q-75161043.html</loc>
<image:image>
<image:title>Prisys Biotech 2024 Q1 Newsletter – Ihr zuverlässiger Spezialist für Studien zu nichtmenschlichen Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024022009580247f09.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-ultrasound-guided-liver-biopsy-enhances-ma-73527825.html</loc>
<image:image>
<image:title>Wie die ultraschallgesteuerte Leberbiopsie die Forschung auf Makakenbasis verbessert</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202312211047254501881.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/guidelines-for-lifetime-use-of-nonhuman-primat-73527826.html</loc>
<image:image>
<image:title>Richtlinien für den lebenslangen Einsatz nichtmenschlicher Primaten in der biomedizinischen Forschung: Eine Perspektive der Prisys-Biotechnologie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202402271428388db72.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/non-human-primates-a-brief-introduction-to-th-73001177.html</loc>
<image:image>
<image:title>Nichtmenschliche Primaten: Eine kurze Einführung in ihre biologischen Eigenschaften</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n202402271431193773d.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/exhibition-review-prisys-biotech-shines-at-t-72674701.html</loc>
<image:image>
<image:title>Ausstellungsrückblick|Prisys Biotech glänzt auf der Jahrestagung der American Society For Neuroscience (SfN 2023)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202311211050557965049.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/meet-prisys-biotech-at-the-society-for-neurosc-72321331.html</loc>
<image:image>
<image:title>Treffen Sie Prisys Biotech auf der Jahrestagung der Society for Neuroscience (SfN 2023)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202311071007243112725.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/world-stroke-day-focus-on-ischemic-stroke-an-72321332.html</loc>
<image:image>
<image:title>Welttag des Schlaganfalls|Schwerpunkt auf Tiermodellen und Pharmakologie für ischämische Schlaganfälle</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202310292017544133660.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-invites-you-to-attend-sapa-chin-72321330.html</loc>
<image:image>
<image:title>Prisys Biotech lädt Sie zur Teilnahme an der SAPA-China-Jahrestagung im Jahr 2023 ein</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202310271316191263008.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/world-alzheimer-s-day-the-challenges-and-sol-72321333.html</loc>
<image:image>
<image:title>Welt-Alzheimer-Tag|Die Herausforderungen und Lösungen für die Entwicklung von AD-Arzneimitteln</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202309211504565472671.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-s-cynomolgus-macaque-animal-mod-72321329.html</loc>
<image:image>
<image:title>Das Cynomolgus-Makaken-Tiermodell von Prisys Biotech hilft bei der Entwicklung neuer gerinnungshemmender Medikamente</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202309182207050266461.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-providing-high-quality-animal-experime-70941459.html</loc>
<image:image>
<image:title>Prisys: Bereitstellung hochwertiger Tierversuchsdienstleistungen für den neuartigen Antikoagulationsfaktor-XI-Antikörper BJTJ-1837</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202308311332528401166.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/method-for-establishing-a-cynomolgus-monkey-mo-70941455.html</loc>
<image:image>
<image:title>Methode zur Etablierung eines Cynomolgus-Affen-Modells für Hypertriglyceridämie und ihre Anwendung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202308212156285814136.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacology-main-parameters-and-significance-70941457.html</loc>
<image:image>
<image:title>Pharmakologie: Hauptparameter und Bedeutung der Pharmakokinetik (PK)</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202308091145033318894.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/preclinical-pharmacology-evaluation-of-oncolyt-70941456.html</loc>
<image:image>
<image:title>Präklinische pharmakologische Bewertung von Arzneimitteln gegen onkolytische Viren</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202308071041585027430.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/0-70941460.html</loc>
<image:image>
<image:title>Wie kleine Nukleinsäure-Medikamente die Behandlung von ZNS-Erkrankungen verändern können: Erkenntnisse von Prisys Biotechnology, einem führenden CRO-Anbieter von NHP-Erkrankungsmodellen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202308041018581481730.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/pharmacokinetics-research-strategies-and-case-70941461.html</loc>
<image:image>
<image:title>Pharmakokinetik, Forschungsstrategien und Fallstudien zu Peptidarzneimitteln</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202308031715493686411.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/key-research-points-of-adc-drug-pk-69658298.html</loc>
<image:image>
<image:title>Wichtige Forschungspunkte der ADC Drug PK</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202307302137108622628.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotechnology-a-leader-in-nhp-cns-dise-69658689.html</loc>
<image:image>
<image:title>Prisys Biotechnology: Führend in der NHP-Forschungsplattform zur Modellierung von ZNS-Erkrankungen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202307252159358927114.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-to-lose-weight-and-control-diabetes-with-g-69309414.html</loc>
<image:image>
<image:title>So verlieren Sie Gewicht und kontrollieren Diabetes mit GLP-1-Produkten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202307162139405018976.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-china-monkey-help-to-conduct-preclinical-r-69309399.html</loc>
<image:image>
<image:title>Wie trägt China Monkey zur Effizienz der präklinischen Forschung bei?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240227143532bd79a.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/what-is-the-efficiency-of-rnai-69309375.html</loc>
<image:image>
<image:title>Was ist die Effizienz von RNAi?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202307092210201669077.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/large-animal-experiment-public-service-platfor-69309376.html</loc>
<image:image>
<image:title>Öffentliche Plattform für Großtierversuche von Prisys Biotech: Kostengünstige und hocheffiziente Lösung für Großtierversuche</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n2024022714394317bcf.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-aav-gene-therapy-can-save-your-vision-the-69143640.html</loc>
<image:image>
<image:title>Wie die AAV-Gentherapie Ihre Sehkraft retten kann: Die neuesten Durchbrüche aus nichtmenschlichen Primatenstudien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202307022231508642715.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-showcases-non-human-primate-mod-69143649.html</loc>
<image:image>
<image:title>Prisys Biotech stellt auf der Jahrestagung der japanischen Gesellschaft für Toxikologie eine Modellplattform für nichtmenschliche Primaten vor</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202306272201578501988.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-promising-future-of-aav-gene-therapy-in-no-69143646.html</loc>
<image:image>
<image:title>Die vielversprechende Zukunft der AAV-Gentherapie bei nichtmenschlichen Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202306232107539553735.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/what-are-lipid-nanoparticles-for-gene-therapy-69143647.html</loc>
<image:image>
<image:title>Was sind Lipid-Nanopartikel für die Gentherapie?</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202306182144004132789.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-invites-you-to-participate-in-t-69143645.html</loc>
<image:image>
<image:title>Prisys Biotech lädt Sie zur Teilnahme an der 50. Jahrestagung der japanischen Gesellschaft für Toxikologie (JSOT) ein</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202306160930293342952.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/immunotoxicity-test-drug-safety-evaluation-pr-69143648.html</loc>
<image:image>
<image:title>Immuntoxizitätstest, Arzneimittelsicherheitsbewertung – PRISYS BIOTECH</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202306102132091628389.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/an-optimal-animal-model-of-ischemic-stroke-est-68306362.html</loc>
<image:image>
<image:title>Ein optimales Tiermodell für ischämischen Schlaganfall, erstellt durch digitale Subtraktionsangiographie-gesteuerte autologe Thromben bei Cynomolgus-Affen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202306051532328723304.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/why-you-should-care-about-non-human-primates-68103475.html</loc>
<image:image>
<image:title>Warum Sie sich bei der Forschung und Entwicklung von Nukleinsäure-Arzneimittelverabreichungssystemen für nichtmenschliche Primaten interessieren sollten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202305282122338248983.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/meet-prisys-biotech-at-70th-jalas-68103464.html</loc>
<image:image>
<image:title>Treffen Sie Prisys Biotech auf der 70. JALAS 2023!</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202305232011515935612.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/gene-therapy-shines-with-new-approvals-for-rar-68103476.html</loc>
<image:image>
<image:title>Gentherapie glänzt mit neuen Zulassungen für seltene Krankheiten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202305162133347179081.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/revolutionizing-drug-discovery-nhp-68103463.html</loc>
<image:image>
<image:title>Revolutionierung der Arzneimittelforschung: Wie nichtmenschliche Primaten das SiRNA-Screening für schnellere und effizientere Ergebnisse optimieren</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/39406/news/n20240227144111404cb.png</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/maximizing-sirna-pharmacology-efficiency-67242824.html</loc>
<image:image>
<image:title>Maximierung der Effizienz der SiRNA-Pharmakologie mit nichtmenschlicher Primatenforschung</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202305022215194112233.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/how-nonhuman-primates-can-revolutionize-sirna-67242823.html</loc>
<image:image>
<image:title>Wie nichtmenschliche Primaten die SiRNA-Forschung revolutionieren können: Ein umfassender Leitfaden</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304272138362221911.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/celebrating-world-day-for-laboratory-animals-67242826.html</loc>
<image:image>
<image:title>Feiern zum Welttag der Versuchstiere: Warum sich Prisys für die Förderung der Gesundheit von nichtmenschlichen Primaten einsetzt</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304242046033664975.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/maximizing-crispr-cas9-research-efficiency-wit-67242827.html</loc>
<image:image>
<image:title>Maximierung der CRISPR/Cas9-Forschungseffizienz mit nichtmenschlichen Primatenmodellen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304221149520486556.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/unleashing-the-therapeutic-potential-67242822.html</loc>
<image:image>
<image:title>Das therapeutische Potenzial freisetzen: Warum die Investition in Nukleinsäure-Medikamente die Zukunft der Medizin ist</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304200850383332884.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/unlocking-the-potential-of-nonhuman-primates-67242825.html</loc>
<image:image>
<image:title>Erschließung des Potenzials nichtmenschlicher Primaten zur Verbesserung der Wirkstoff-Target-Erkennung für Gentherapien</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304142148160397375.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/world-parkinsons-disease-day-67242821.html</loc>
<image:image>
<image:title>Vereinen Sie sich für Parkinson: Schließen Sie sich den Händen, um das Bewusstsein für den Welt-Parkinson-Tag zu schärfen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304111648126878455.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/nhp-effectively-in-gene-therapy-67242828.html</loc>
<image:image>
<image:title>Wie man nichtmenschliche Primaten effektiv bei der Sicherheitsbewertung von Gentherapien einsetzt</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304102117431547381.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/gene-therapy-toxicology-66267921.html</loc>
<image:image>
<image:title>Gentherapie-Toxikologieforschung mit Nonhuam-Primaten</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202304052050241172289.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/dmpk-study-for-gene-therapy-66085978.html</loc>
<image:image>
<image:title>Ein umfassender Leitfaden zur Durchführung einer DMPK-Studie zur Gentherapie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303292053463875854.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/gene-therapy-nhp-model-66085980.html</loc>
<image:image>
<image:title>Revolutionierung der medizinischen Forschung: Gentherapie-Durchbrüche in Modellen nichtmenschlicher Primatenkrankheiten!</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303282057377312705.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/top-10-popular-questions-related-to-gene-thera-66085985.html</loc>
<image:image>
<image:title>Top 10 Popular Questions Related To Gene Therapy</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303241229248740600.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-biotech-non-human-primate-pharmacology-66085984.html</loc>
<image:image>
<image:title>Prisys Biotech: Nicht-menschliche Primaten-Pharmakologie für die Gentherapie</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303241128310077112.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/supporting-women-s-health-a-look-into-endomet-66085981.html</loc>
<image:image>
<image:title>Unterstützung der Gesundheit von Frauen: Ein Blick in die Endometriose</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303080917443223214.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-sot2023-66085979.html</loc>
<image:image>
<image:title>PRISYS und Taichu Group arbeiten für die SOT-Ausstellung im Jahr 2023 zusammen</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303101009207805940.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/do-we-need-further-studies-for-pain-assessment-66085982.html</loc>
<image:image>
<image:title>Brauchen wir weitere Studien zur Schmerzbewertung? -NHP</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303081329477852711.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/prisys-celebrating-world-wildlife-day-66085987.html</loc>
<image:image>
<image:title>Feiern Sie mit uns den Welttierschutztag</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303031713469632535.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/the-construction-of-prisys-shanghai-nhp-r-d-ce-66085983.html</loc>
<image:image>
<image:title>Prisys Shanghai NHP R&amp;D Center eröffnet und markiert einen Meilenstein in der pharmazeutischen Forschung und Entwicklung in China</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303081340054460581.jpg</image:loc>
</image:image>
</url>
<url>
<loc>https://de.prisysbiotech.com/news/meetprisys-sot2023-66085977.html</loc>
<image:image>
<image:title>Meet Prisys @ Booth No. 1434 in The Upcoming SOT Conference | US-Roadshow</image:title>
<image:loc>https://de.prisysbiotech.com/uploads/202339406/n202303031705254453292.jpg</image:loc>
</image:image>
</url>
</urlset>